Company Overview and News


Add BSX
to your dashboard

Headline News

The Top 10 Value Stocks in the S&P 500

17h investorplace
“Value will have its day in the sun.” That’s what John Buckingham, a veteran value investor and chief investment officer at AFAM Capital Asset Management, recently told Kiplinger in an interview. (264-1)

Will Varian Medical Systems’ Sales Decline Again in 1Q18?

19h editors.aws.marketrealist
Varian Medical Systems (VAR) is set to announce its 1Q18 earnings results on January 24, 2018. According to Wall Street analysts’ estimates, the company will report total revenues of $636.8 million in 1Q18, representing a YoY (year-over-year) decline of 16.6%. It has been almost a year since the company spun off its imaging components business into Varex Imaging. It expects to register growth in sales beginning in fiscal 2Q18. (102-0)

Analyst Recommendations for Varian Medical Systems before 1Q18

20h editors.aws.marketrealist
Varian Medical Systems (VAR) will announce its 1Q18 earnings results on January 24, 2018. In January 2017, the company spun off its imaging components business into Varex Imaging (VREX). It has since been focusing on its core capabilities and has been taking initiatives and implementing strategic plans to establish itself as the leading cancer management company in the world. Read How Is Varian Positioned for 2018 after 2017 Transformation? for a detailed discussion on Varian’s future growth plans and market position. (38-0)

Boston Scientific's Positive SCS Trial Aids Neuromodulation

2018-01-16 zacks
Boston Scientific Corporation’s (BSX - Free Report) successful result from its WHISPER randomized controlled trial (RCT) further boosts its neuromodulation business. This announcement follows the recent FDA approval of Spectra WaveWriter Spinal Cord Stimulator System (SCS) within the neuromodulation arm. (102-0)

Boston Scientific Fortifies Pain Therapy Arm With FDA Nod

2018-01-15 zacks
Boston Scientific (BSX - Free Report) is hitting headlines with successive new developments, the latest feat being the company’s Spectra WaveWriter Spinal Cord Stimulator System (SCS) getting an FDA nod. Per Boston Scientific, this is the only FDA-approved SCS system to provide paresthesia-based and sub-perception therapies. (83-0)

Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’

2018-01-12 editors.aws.marketrealist
On January 9, 2018, Mizuho Securities upgraded Teva Pharmaceutical Industries (TEVA) from a “neutral” to a “buy” rating. Mizuho is a leading Japanese investment banking firm. Analyst Irina Koffler at Mizuho raised the price target on TEVA stock from $16 to $23. The stock rose 1.4% that day, and the BLDRS Europe Select ADR ETF (ADRU) fell 0.28%. TEVA makes up 0.51% of ADRU’s total portfolio holdings. (163-0)

MedTech Tax Resumes in 2018, 3 Stocks to Suffer

2018-01-12 zacks
The year 2018 may bring ample reasons for Americans to cheer from the standpoint of the latest Tax Cuts and Jobs Act that was finally signed by the President on Dec 22. Effective Jan 1, there are seven income tax brackets with five offering reduced tax rates. Corporate tax rates too have been slashed to 21% from 35% earlier. This apart, the new legislation has almost doubled the standard deduction. (59-0)

Boston Scientific gets FDA approval for spinal cord stimulator system that offers non-opioid pain treatment - MarketWatch

2018-01-11 marketwatch
Shares of Boston Scientific Corp. BSX, -1.57% rose 1.7% in premarket trade Thursday, after the company said the U.S. Food and Drug Administration has approved its Spectra WaveWriter spinal cord simulator system, a non-opioid treatment for chronic pain. "It is the first and only system approved by the FDA to simultaneously provide paresthesia-based and sub-perception therapy," the company said in a statement. (34-0)

Boston Scientific Rises 8.3% on Upbeat 4Q Preliminary Sales

2018-01-10 zacks
Boston Scientific (BSX - Free Report) stock gained 8.33% to $27.96 at Jan 9’s close of trading, following the company’s announcement of an upbeat fourth-quarter 2017 preliminary sales performance. Notably, Boston Scientific is slated to release fourth-quarter and 2017 results on Feb 1, before the market opens. (103-0)

Boston Scientific (BSX) Surges: Stock Moves 8.3% Higher

2018-01-10 zacks
Boston Scientific Corporation (BSX - Free Report) was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $24.79 to $25.97 in the past one month time frame. (45-0)

Wall Street extends New Year rally

2018-01-10 thehindubusinessline
Wall Street's major indexes extended the New Year rally to close at record levels on Tuesday on investor optimism ahead of quarterly earnings reports and hopes for easing tensions with North Korea. (67-0)

Wall Street climbs with boost from healthcare, banks

2018-01-10 moneycontrol
Wall Street's major indexes extended the New Year rally to close at record levels on Tuesday on investor optimism ahead of quarterly earnings reports and hopes for easing tensions with North Korea. (67-0)

Wall Street climbs with boost from healthcare, banks

2018-01-10 themalaymailonline
A trader works on the floor of the New York Stock Exchange in New York, December 27, 2013. — Reuters picNEW YORK, Jan 10 — Wall Street’s major indexes extended the New Year rally to close at record levels yessterday on investor optimism ahead of quarterly earnings reports and hopes for easing tensions with North Korea. (67-0)

CUSIP: 101137107